Oxytocin Pharmacokinetics and Pharmacodynamics
Recruiting
Phase 2
Interventional Study
Post Partum Hemorrhage
Cesarean Section Complications
Blood Loss
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 50
- Sex
- Female
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 100 (estimated)
- Sponsor
- University of Chicago · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Oxytocin is the first-line drug to promote contraction of the uterus and prevent atony immediately after delivery. Nonetheless, unpredictable uterine atony refractory to oxytocin affects roughly 250,000 parturients annually in the U.S. and rates are increasing. This two-part study will measure the action of oxytocin at cesarean delivery. The first part will measure the pharmacokinetics of a single…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria
* 18-50 years old
* intrauterine pregnancy
* term (\>39 weeks gestation or 37-39 weeks gestation with fetal or maternal medical indication for delivery) pregnancy
* non-emergent (scheduled or unscheduled) cesarean delivery
Exclusion Criteria:
* allergy or contraindication to ox…
Contacts